Jeremy G. Chadwick's most recent trade in Kymera Therapeutics Inc was a trade of 4,500 Common Stock done at an average price of $80.0 . Disclosure was reported to the exchange on May 26, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 80.02 per share. | 26 May 2026 | 4,500 | 48,848 | - | 80.0 | 360,111 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 79.39 per share. | 26 May 2026 | 3,800 | 53,348 | - | 79.4 | 301,691 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 78.36 per share. | 26 May 2026 | 3,730 | 57,472 | - | 78.4 | 292,271 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 81.50 per share. | 26 May 2026 | 3,679 | 44,618 | - | 81.5 | 299,850 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 82.08 per share. | 26 May 2026 | 600 | 44,018 | - | 82.1 | 49,246 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 80.71 per share. | 26 May 2026 | 551 | 48,297 | - | 80.7 | 44,470 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 79.17 per share. | 26 May 2026 | 324 | 57,148 | - | 79.2 | 25,651 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 90.00 per share. | 22 Apr 2026 | 300 | 61,202 | - | 90 | 27,000 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Apr 2026 | 200 | 58,263 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.50 per share. | 22 Apr 2026 | 200 | 61,502 | - | 43.5 | 8,700 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.17 per share. | 22 Apr 2026 | 100 | 61,302 | - | 30.2 | 3,017 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Apr 2026 | 100 | 45,434 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 90.00 per share. | 14 Apr 2026 | 5,251 | 61,202 | - | 90.0 | 472,598 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.17 per share. | 14 Apr 2026 | 4,466 | 65,668 | - | 30.2 | 134,739 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2026 | 4,466 | 45,534 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2026 | 1,300 | 58,463 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 90.00 per share. | 14 Apr 2026 | 1,300 | 61,202 | - | 90 | 117,000 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.50 per share. | 14 Apr 2026 | 1,300 | 62,502 | - | 43.5 | 56,550 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2026 | 785 | 59,763 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.50 per share. | 14 Apr 2026 | 785 | 66,453 | - | 43.5 | 34,148 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2026 | 14,640 | 68,633 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.64 per share. | 31 Mar 2026 | 14,640 | 75,842 | - | 29.6 | 433,930 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 85.41 per share. | 31 Mar 2026 | 13,540 | 62,302 | - | 85.4 | 1,156,511 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 85.38 per share. | 31 Mar 2026 | 7,600 | 61,202 | - | 85.4 | 648,882 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.64 per share. | 31 Mar 2026 | 7,600 | 68,802 | - | 29.6 | 225,264 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2026 | 7,600 | 83,273 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 86.05 per share. | 31 Mar 2026 | 1,100 | 61,202 | - | 86.1 | 94,655 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.64 per share. | 23 Mar 2026 | 84,400 | 152,452 | - | 29.6 | 2,501,616 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Mar 2026 | 84,400 | 115,600 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 77.21 per share. | 23 Mar 2026 | 52,975 | 76,721 | - | 77.2 | 4,089,983 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 80.26 per share. | 23 Mar 2026 | 24,727 | 61,202 | - | 80.3 | 1,984,554 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 29.64 per share. | 23 Mar 2026 | 24,727 | 85,929 | - | 29.6 | 732,908 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Mar 2026 | 24,727 | 90,873 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 76.73 per share. | 23 Mar 2026 | 22,756 | 129,696 | - | 76.7 | 1,746,134 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 78.40 per share. | 23 Mar 2026 | 8,214 | 68,507 | - | 78.4 | 643,950 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 79.87 per share. | 23 Mar 2026 | 6,105 | 62,402 | - | 79.9 | 487,609 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 80.05 per share. | 23 Mar 2026 | 1,200 | 61,202 | - | 80.1 | 96,060 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.50 per share. | 11 Mar 2026 | 20,000 | 93,810 | - | 43.5 | 870,000 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2026 | 20,000 | 60,548 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 83.10 per share. | 11 Mar 2026 | 12,882 | 79,163 | - | 83.1 | 1,070,511 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 83.72 per share. | 11 Mar 2026 | 11,111 | 68,052 | - | 83.7 | 930,207 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 82.13 per share. | 11 Mar 2026 | 1,765 | 92,045 | - | 82.1 | 144,955 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 29.30 per share. | 23 May 2025 | 2,575 | 66,420 | - | 29.3 | 75,436 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 25,000 | 69,183 | - | 0 | Common Stock | |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 30.33 per share. | 03 Mar 2025 | 1,131 | 68,052 | - | 30.3 | 34,300 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 31.00 per share. | 03 Mar 2025 | 252 | 67,800 | - | 31.0 | 7,813 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 34.99 per share. | 23 May 2024 | 2,575 | 44,183 | - | 35.0 | 90,105 | Common Stock |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 80,548 | 80,548 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 13,425 | 46,758 | - | 0 | Common Stock | |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2023 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Kymera Therapeutics Inc | Jeremy G. Chadwick | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2023 | 33,333 | 33,333 | - | 0 | Common Stock |